Clinical Trial

Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)

Study acronym: K-ACCELERATE

Enrolling by Invitation

Record status

This record was last updated July 16, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Summary

To evaluate the diagnostic performance of blood-based SPOT-MAS test in symptomatic individuals, the investigators sought to launch a prospective multicenter study, named K-ACCELERATE. The study aims to recruit 1,000 participants who develop symptoms and signs specific to the top five common cancer types including breast, colorectal, gastric, liver and lung cancer. Primary objective: Evaluate the performance of the SPOT-MAS test in detecting cancer in symptomatic populations. Secondary objectives: Evaluate the feasibility of incorporating SPOT-MAS as a triage test into primary care to increase the detection rates of malignant cancer while minimizing unnecessary referrals to invasive procedures.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2024-04-25; most recent amendment 2025-07-12.

Status change: Recruiting → Enrolling by Invitation 2025-07-12

Trial Details

NCT Number	NCT06391749
Lead Sponsor	Gene Solutions Collaborators: University of Medicine and Pharmacy at Ho Chi Minh City
Conditions	Cancer Colon, Cancer, Liver, Cancer, Lung, Cancer, Breast, Cancer, Gastric
Enrollment	1,000 participants
Start Date	2024-07-30
Primary Completion	2026-07 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2025-07-16